Tvardi director granted 6,000 stock options

Tvardi Therapeutics, Inc. director Susan Shiff, Ph.D. received a grant of stock options covering 6,000 shares of common stock.

Accepted by SEC EDGAR 06/11/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. director Susan Shiff, Ph.D. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036. 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, subject to her continuous service. Following this grant, she holds 6,000 stock options directly.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider Shiff Susan Ph.D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	6,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Stock options granted: 6,000 options Exercise price: $2.78 per share Underlying shares: 6,000 shares +3 more

6 metrics

Stock options granted 6,000 options Grant to director Susan Shiff, Ph.D.

Exercise price $2.78 per share Strike price for granted stock options

Underlying shares 6,000 shares Common stock underlying granted options

Vesting date trigger June 9, 2027 Earlier of this date or next annual meeting

Option expiration June 8, 2036 Expiration date of stock options

Post-grant derivative holdings 6,000 options Total stock options held after transaction

Key Terms

Stock Option (right to buy), grant/award acquisition, Common Stock, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tvardi Therapeutics (TVRD) disclose in this Form 4 for Susan Shiff?

Tvardi Therapeutics reported a stock option grant to director Susan Shiff, Ph.D. for 6,000 shares of common stock. The award is part of her director compensation and does not reflect an open-market purchase or sale of shares.

How many Tvardi Therapeutics (TVRD) options were granted to Susan Shiff and at what price?

Susan Shiff received 6,000 stock options covering Tvardi common shares with an exercise price of $2.78 per share. This means she can buy up to 6,000 shares at $2.78 if the options vest and she chooses to exercise them.

When do Susan Shiff’s Tvardi Therapeutics (TVRD) stock options vest?

All of Susan Shiff’s 6,000 stock options vest 100% on the earlier of June 9, 2027 or Tvardi’s next annual meeting of stockholders. Vesting is conditioned on her maintaining continuous service with the company through the applicable vesting date.

What is the expiration date of Susan Shiff’s Tvardi Therapeutics (TVRD) stock options?

The granted stock options expire on June 8, 2036. After that date, any unexercised portion of the 6,000 options will lapse. Until expiration, she may exercise vested options at the fixed exercise price of $2.78 per share.

Is Susan Shiff’s Tvardi Therapeutics (TVRD) Form 4 transaction a market purchase or sale?

This Form 4 reports a grant/award acquisition of stock options, not an open-market trade. Tvardi granted her 6,000 options at a $2.78 exercise price as compensation, and no shares were bought or sold on the public market in this transaction.

How many Tvardi Therapeutics (TVRD) derivatives does Susan Shiff hold after this grant?

Following this grant, Susan Shiff directly holds 6,000 stock options relating to Tvardi common stock. These options vest on the specified schedule and are exercisable at $2.78 per share until their expiration on June 8, 2036, assuming continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shiff Susan Ph.D.

(Last) (First) (Middle)

C/O TVARDI THERAPEUTICS, INC.

3 SUGAR CREEK CTR BLVD, STE 525

(Street)

SUGAR LAND TEXAS 77478

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.78	06/09/2026		A		6,000		(1)	06/08/2036	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Dan Conn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)